International "Comparability" Of Regulatory Standards May Be FDA's Solution To GMP Oversight
This article was originally published in PharmAsia News
Executive Summary
FDA may begin to rely on foreign government oversight of manufacturing even if the standards for the overseas regulators do not exactly match those in the U.S
You may also be interested in...
Mylan Grabs More FDA Globalization Talent
Steve Lynn, director of CDER’s Office of Manufacturing and Product Quality, will take an executive global compliance position.
U.S. FDA Issues Warning Letters To Chinese Firms As Agency Tightens Foreign Field Inspections Program
The agency requests 16 more inspectors in China in an effort to boost enforcement and training.
Is Silence Golden For Brand Companies On Inspection Fees?
The inspection and establishment fee issue likely will remain a prickly subject for brand companies in the coming years, especially if a program is successfully launched for generics.